Literature DB >> 9300223

Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.

M E Griffin1, D McInerney, A Fraser, A H Johnson, P B Collins, D Owens, G H Tomkin.   

Abstract

Autoantibodies to oxidized low density lipoprotein have been shown to be an independent predictor of the progression of carotid atherosclerosis. This study examines the relationship between low density lipoprotein fatty acid composition and autoantibodies to both malondialdehyde-modified and copper-oxidized low density lipoprotein in non-diabetic patients with (n = 17), and without (n = 18), definite evidence of previous myocardial infarction. The third group were non-insulin-dependent diabetic patients with no evidence of atherosclerosis (n = 15) and the fourth group were patients with non-insulin-dependent diabetes (n = 17) who had definite evidence of previous myocardial infarction. Fatty acids were measured by gas-liquid chromatography. Antibodies to malondialdehyde-modified low density lipoprotein and copper-oxidized low density lipoprotein were determined by an ELISA method. Autoantibodies to copper-oxidized low density lipoprotein were significantly higher in the non-diabetic patients with heart disease when compared to any other group (p < 0.05). Autoantibodies to malondialdehyde-modified low density lipoprotein were significantly higher in the non-diabetic subjects with heart disease and in both diabetic groups compared to non-diabetic subjects without coronary heart disease (p < 0.05). Linoleic acid (%) in low density lipoprotein did not differ between groups groups but arachidonic acid (%) was significantly lower in both diabetic and non-diabetic patients with coronary heart disease (p < 0.05). The diabetic patients with low antibodies had 39.6 +/- 2.2% polyunsaturated fatty acids in their low density lipoprotein while diabetic patients with high antibodies had 46.7 +/- 1.2% polyunsaturates in their low density lipoprotein (p < 0.01). This study confirms the association between antibodies to oxidized low density lipoprotein and coronary heart disease and shows raised low density lipoprotein antibody levels in diabetic patients with and without demonstrable atherosclerosis. In the diabetic patients, those with high antibody levels had high polyunsaturated fatty acid levels in their LDL suggesting a possible role for dietary intervention.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300223     DOI: 10.1002/(SICI)1096-9136(199709)14:9<741::AID-DIA468>3.0.CO;2-A

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

1.  Tandem mass spectrometry of model peptides modified with trans-2-hexenal, a product of lipid peroxidation.

Authors:  A G Baker; D Wiesler; M V Novotny
Journal:  J Am Soc Mass Spectrom       Date:  1999-07       Impact factor: 3.109

2.  Conway Memorial Lecture 2002. The dyslipidaemia of diabetes: lessons in the pathogenesis of atherosclerosis.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Oct-Dec       Impact factor: 1.568

3.  Robert Graves Memorial Lecture. Diabetes and atherosclerosis--a gut review.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

Review 4.  Hyperglycaemia: the relation to dyslipidaemia and atherosclerosis.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Jul-Sep       Impact factor: 1.568

Review 5.  Diabetes, oxidative stress and physical exercise.

Authors:  Mustafa Atalay; David E Laaksonen
Journal:  J Sports Sci Med       Date:  2002-03-04       Impact factor: 2.988

6.  Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus.

Authors:  S M Trigwell; P M Radford; S R Page; A C Loweth; R F James; N G Morgan; I Todd
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

7.  Endothelial vasodilatory function is predicted by circulating apolipoprotein B and HDL in healthy humans.

Authors:  Peter Steer; Johannes Hulthe; Jonas Miligård; Dennis M Sarabi; Samar Basu; Bengt Vessby; Lars Lind
Journal:  Lipids       Date:  2002-12       Impact factor: 1.880

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.